港股异动|大成生化科技复牌涨逾20%拟获汇港投资入股约16.7%
格隆汇7月22日丨大成生化科技(0809.HK)今日复牌涨20.33%,现报0.148港元,暂成交1141万港元,最新总市值9.47亿港元。
大成生化科技上周五(19日)下午三时三分起短暂停牌,以待公司发出一份有关认购公司股份(其构成公司的内幕消息)的公告,停牌前收报0.123港元,涨8.85%。
同日晚间发布公告称,向汇港投资配售合共12.798亿股新股,占扩大后股本约16.7%,配售价每股0.1港元,较停牌前收盘价折让约18.7%。所得款项净额约1.279亿港元,资金会用于偿还银行借贷利息、偿还集团中国附属公司的贸易及其他应付款项等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.